Concepedia

Marianne Rosamilia

MR

Statistics

Publications

4

Citations

870

H-Index

4

Active since

2004

Affiliations

Novartis (Switzerland)(Current)

Université de Montréal

Novartis (United States)

The University of Texas MD Anderson Cancer Center

Marianne Rosamilia is an author at Novartis (Switzerland) specializing in medicine, cancer therapeutics, and tumor microenvironment.

Top concepts

Publications per year

2004–2011

4

Publications

4

Pharmacokinetics and Pharmacodynamics of Imatinib in a Phase I Trial With Chronic Myeloid Leukemia Patients

Bin Peng, Michael Hayes, Debra Resta et al. · Journal of Clinical Oncology · 2004 · 465 citations · Full text

Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study

Martin Champagne, Renaud Capdeville, Mark Krailo et al. · Blood · 2004 · 236 citations

An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

Viktor Grünwald, Pierre I. Karakiewicz, Sevil Bavbek et al. · European Journal of Cancer · 2011 · 87 citations

, , +6

Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome

Gail J. Roboz, Francis J. Giles, Alan F. List et al. · Leukemia · 2006 · 82 citations

, , +9

Rows per page

1–4 of 4